Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer
Pannuti, F.; Martoni, A.; Piana, E.; Tomasi, L.; Grieco, A.; Farris, A.; Saccani, F.; Baroni, M.
Chemioterapia International Journal of the Mediterranean Society of ChemoTherapy 3(4): 211-215
1984
ISSN/ISBN: 0392-906X PMID: 6241846 Document Number: 241277
High dose MAP (medroxyprogesterone acetate) and TAM (tamoxifen) were administered orally to 31 postmenopausal patients with advanced breast cancer. CR (complete remission) was achieved in 1 (3%) and PR (partial remission) in 11 (32%) patients for a median duration of 12 months. The treatment was well tolerated and in no instance was interrupted because of toxicity. This study does not support the hypothesis that the combination of MAP and TAM gives better results than the single agents.